Biomarker concordance between primary colorectal cancer and its metastases
2019; Elsevier BV; Volume: 40; Linguagem: Inglês
10.1016/j.ebiom.2019.01.050
ISSN2352-3964
AutoresDilraj Bhullar, Jorge Barriuso, S. Mullamitha, Mark Saunders, Sarah O’Dwyer, Omer Aziz,
Tópico(s)Gastric Cancer Management and Outcomes
ResumoBackgroundThe use of biomarkers to target anti-EGFR treatments for metastatic colorectal cancer (CRC) is well-established, requiring molecular analysis of primary or metastatic biopsies. We aim to review concordance between primary CRC and its metastatic sites.MethodsA systematic review and meta-analysis of all published studies (1991–2018) reporting on biomarker concordance between primary CRC and its metastatic site(s) was undertaken according to PRISMA guidelines using several medical databases. Studies without matched samples or using peripheral blood for biomarker analysis were excluded.Findings61 studies including 3565 patient samples were included. Median biomarker concordance for KRAS (n = 50) was 93.7% [67Voutsina A. Tzardi M. Kalikaki A. Zafeiriou Z. Papadimitraki E. Papadakis M. et al.Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer.Mod Pathol. 2013 Aug 31; 26: 302Summary Full Text Full Text PDF PubMed Scopus (47) Google Scholar, 68Vakiani E. Janakiraman M. Shen R. Sinha R. Zeng Z. Shia J. et al.Comparative genomic analysis of primary versus metastatic colorectal carcinomas.J Clin Oncol. 2012 Aug; 30: 2956-2962Crossref PubMed Scopus (222) Google Scholar, 69Vermaat J.S. Nijman I.J. Koudijs M.J. Gerritse F.L. Scherer S.J. Mokry M. et al.Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment.Clin Cancer Res. 2012 Feb; 18: 688-699Crossref PubMed Scopus (127) Google Scholar, 70Knijn N. Mekenkamp L.J.M. Klomp M. Vink-Borger M.E. Tol J. Teerenstra S. et al.KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients.Br J Cancer. 2011 Mar; 104: 1020-1026Crossref PubMed Scopus (238) Google Scholar, 71Park J.H. Han S.-W. Oh D.-Y. Im S.-A. Jeong S.-Y. Park K.J. et al.Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.Cancer Chemother Pharmacol. 2011; 68: 1045-1055Crossref PubMed Scopus (56) Google Scholar, 72Watanabe T. Kobunai T. Yamamoto Y. Matsuda K. Ishihara S. Nozawa K. et al.Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer.Dis Colon Rectum. 2011 Sep; 54: 1170-1178Crossref PubMed Scopus (0) Google Scholar, 73Baldus S.E. Schaefer K.-L. Engers R. Hartleb D. Stoecklein N.H. Gabbert H.E. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.Clin Cancer Res. 2010 Feb; 16: 790-799Crossref PubMed Scopus (382) Google Scholar, 74Italiano A. Hostein I. Soubeyran I. Fabas T. Benchimol D. Evrard S. et al.KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.Ann Surg Oncol. 2010 May; 17: 1429-1434Crossref PubMed Scopus (101) Google Scholar, 75Mariani P. Lae M. Degeorges A. Cacheux W. Lappartient E. Margogne A. et al.Concordant analysis of KRAS status in primary colon carcinoma and matched metastasis.Anticancer Res. 2010 Oct; 30: 4229-4235PubMed Google Scholar, 76Perrone F. Lampis A. Orsenigo M. Di Bartolomeo M. Gevorgyan A. Losa M. et al.PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients.Ann Oncol Off J Eur Soc Med Oncol. 2009 Jan; 20: 84-90Summary Full Text Full Text PDF PubMed Scopus (0) Google Scholar, 77Cejas P. Lopez-Gomez M. Aguayo C. Madero R. de Castro Carpeno J. Belda-Iniesta C. et al.KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis.PLoS One. 2009 Dec; 4e8199Crossref Scopus (130) Google Scholar, 78Garm Spindler K.-L. Pallisgaard N. Rasmussen A.A. Lindebjerg J. Andersen R.F. Cruger D. et al.The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer.Ann Oncol Off J Eur Soc Med Oncol. 2009 May; 20: 879-884Summary Full Text Full Text PDF PubMed Scopus (0) Google Scholar, 79Molinari F. Martin V. Saletti P. De Dosso S. Spitale A. Camponovo A. et al.Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant.Br J Cancer. 2009 Apr 7; 100: 1087-1094Crossref PubMed Scopus (0) Google Scholar, 80Gattenlöhner S. Etschmann B. Kunzmann V. Thalheimer A. Hack M. Kleber G. et al.Concordance of KRAS/BRAF mutation status in metastatic colorectal cancer before and after anti-EGFR therapy.J Oncol. 2009 Mar 10; 2009: 831626Crossref PubMed Google Scholar, 81Etienne-Grimaldi M.-C. Formento J.-L. Francoual M. Francois E. Formento P. Renee N. et al.K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy.Clin Cancer Res. 2008 Aug; 14: 4830-4835Crossref PubMed Scopus (0) Google Scholar, 82Santini D. Loupakis F. Vincenzi B. Floriani I. Stasi I. Canestrari E. et al.High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice.Oncologist. 2008 Dec; 13: 1270-1275Crossref PubMed Scopus (205) Google Scholar, 83Artale S. Sartore-Bianchi A. Veronese S.M. Gambi V. Sarnataro C.S. Gambacorta M. et al.Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer.J Clin Oncol. 2008; 26 (Official Journal of the American Society of Clinical Oncology. United States): 4217-4219Crossref PubMed Scopus (208) Google Scholar, 84Gattenlohner S. Germer C. Muller-Hermelink H.-K. K-ras mutations and cetuximab in colorectal cancer.N Engl J Med. 2008; 360 (United States. [author reply 835–6]): 835Google Scholar, 85Weber J.-C. Meyer N. Pencreach E. Schneider A. Guerin E. Neuville A. et al.Allelotyping analyses of synchronous primary and metastasis CIN colon cancers identified different subtypes.Int J Cancer. 2007 Feb; 120: 524-532Crossref PubMed Scopus (27) Google Scholar, 86Oliveira C. Velho S. Moutinho C. Ferreira A. Preto A. Domingo E. et al.KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression.Oncogene. 2007 Jan; 26: 158-163Crossref PubMed Scopus (129) Google Scholar, 87Albanese I. Scibetta A.G. Migliavacca M. Russo A. Bazan V. Tomasino R.M. et al.Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations.Biochem Biophys Res Commun. 2004 Dec; 325: 784-791Crossref PubMed Scopus (79) Google Scholar, 88Zauber P. Sabbath-Solitare M. Marotta S.P. Bishop D.T. Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchronous metastases compared with the findings in accompanying adenomas.Mol Pathol. 2003 Jun 17; 56: 137-140Crossref PubMed Google Scholar, 89Tortola S. Steinert R. Hantschick M. Peinado M.A. Gastinger I. Stosiek P. et al.Discordance between K-ras mutations in bone marrow micrometastases and the primary tumor in colorectal cancer.J Clin Oncol. 2001 Jun; 19: 2837-2843Crossref PubMed Scopus (62) Google Scholar, 90Al-Mulla F. Going J.J. Sowden E.T. Winter A. Pickford I.R. Birnie G.D. Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality.J Pathol. 1998 Jun; 185: 130-138Crossref PubMed Scopus (114) Google Scholar, 91Suchy B. Zietz C. Rabes H.M. K-ras point mutations in human colorectal carcinomas: relation to aneuploidy and metastasis.Int J Cancer. 1992 Aug; 52: 30-33Crossref PubMed Google Scholar, 92Losi L. Benhattar J. Costa J. Stability of K-ras mutations throughout the natural history of human colorectal cancer.Eur J Cancer. 1992; 28A: 1115-1120Summary Full Text PDF PubMed Scopus (88) Google Scholar, 93Oudejans J.J. Slebos R.J. Zoetmulder F.A. Mooi W.J. Rodenhuis S. Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver.Int J Cancer. 1991 Dec; 49: 875-879Crossref PubMed Scopus (0) Google Scholar, 94Atreya C.E. Sangale Z. Xu N. Matli M.R. Tikishvili E. Welbourn W. et al.PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival.Cancer Med. 2013 Aug; 2: 496-506Crossref PubMed Scopus (0) Google Scholar, 95Yarom N. Marginean C. Moyana T. Gorn-Hondermann I. Birnboim H.C. Marginean H. et al.EGFR expression variance in paired colorectal cancer primary and metastatic tumors.Cancer Biol Ther. 2010 Sep; 10: 416-421Crossref PubMed Scopus (15) Google Scholar, 96Scartozzi M. Bearzi I. Berardi R. Mandolesi A. Fabris G. Cascinu S. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies.J Clin Oncol. 2004 Dec; 22: 4772-4778Crossref PubMed Scopus (245) Google Scholar, 97Jung J. Kang Y. Lee Y.J. Kim E. Ahn B. Lee E. et al.Comparison of the mismatch repair system between primary and metastatic colorectal cancers using immunohistochemistry.J Pathol Transl Med. 2017 Mar; 51: 129-136Crossref PubMed Scopus (6) Google Scholar, 98Haraldsdottir S. Roth R. Pearlman R. Hampel H. Arnold C.A. Frankel W.L. Mismatch repair deficiency concordance between primary colorectal cancer and corresponding metastasis.Familial Cancer. 2016; 15: 253-260Crossref PubMed Scopus (0) Google Scholar, 99Cohen S.A. Yu M. Baker K. Redman M. Wu C. Heinzerling T.J. et al.The CpG island methylator phenotype is concordant between primary colorectal carcinoma and matched distant metastases.Clin Epigenetics. 2017 May 2; 9: 46Crossref PubMed Scopus (1) Google Scholar, 100Kleist B. Meurer T. Poetsch M. Mitochondrial DNA alteration in primary and metastatic colorectal cancer: different frequency and association with selected clinicopathological and molecular markers.Tumour Biol. 2017 Mar; 39 (1010428317692246)Crossref PubMed Scopus (5) Google Scholar], NRAS (n = 11) was 100% [90Al-Mulla F. Going J.J. Sowden E.T. Winter A. Pickford I.R. Birnie G.D. Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality.J Pathol. 1998 Jun; 185: 130-138Crossref PubMed Scopus (114) Google Scholar, 91Suchy B. Zietz C. Rabes H.M. K-ras point mutations in human colorectal carcinomas: relation to aneuploidy and metastasis.Int J Cancer. 1992 Aug; 52: 30-33Crossref PubMed Google Scholar, 92Losi L. Benhattar J. Costa J. Stability of K-ras mutations throughout the natural history of human colorectal cancer.Eur J Cancer. 1992; 28A: 1115-1120Summary Full Text PDF PubMed Scopus (88) Google Scholar, 93Oudejans J.J. Slebos R.J. Zoetmulder F.A. Mooi W.J. Rodenhuis S. Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver.Int J Cancer. 1991 Dec; 49: 875-879Crossref PubMed Scopus (0) Google Scholar, 94Atreya C.E. Sangale Z. Xu N. Matli M.R. Tikishvili E. Welbourn W. et al.PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival.Cancer Med. 2013 Aug; 2: 496-506Crossref PubMed Scopus (0) Google Scholar, 95Yarom N. Marginean C. Moyana T. Gorn-Hondermann I. Birnboim H.C. Marginean H. et al.EGFR expression variance in paired colorectal cancer primary and metastatic tumors.Cancer Biol Ther. 2010 Sep; 10: 416-421Crossref PubMed Scopus (15) Google Scholar, 96Scartozzi M. Bearzi I. Berardi R. Mandolesi A. Fabris G. Cascinu S. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies.J Clin Oncol. 2004 Dec; 22: 4772-4778Crossref PubMed Scopus (245) Google Scholar, 97Jung J. Kang Y. Lee Y.J. Kim E. Ahn B. Lee E. et al.Comparison of the mismatch repair system between primary and metastatic colorectal cancers using immunohistochemistry.J Pathol Transl Med. 2017 Mar; 51: 129-136Crossref PubMed Scopus (6) Google Scholar, 98Haraldsdottir S. Roth R. Pearlman R. Hampel H. Arnold C.A. Frankel W.L. Mismatch repair deficiency concordance between primary colorectal cancer and corresponding metastasis.Familial Cancer. 2016; 15: 253-260Crossref PubMed Scopus (0) Google Scholar, 99Cohen S.A. Yu M. Baker K. Redman M. Wu C. Heinzerling T.J. et al.The CpG island methylator phenotype is concordant between primary colorectal carcinoma and matched distant metastases.Clin Epigenetics. 2017 May 2; 9: 46Crossref PubMed Scopus (1) Google Scholar, 100Kleist B. Meurer T. Poetsch M. Mitochondrial DNA alteration in primary and metastatic colorectal cancer: different frequency and association with selected clinicopathological and molecular markers.Tumour Biol. 2017 Mar; 39 (1010428317692246)Crossref PubMed Scopus (5) Google Scholar], BRAF (n = 22) was 99.4% [80Gattenlöhner S. Etschmann B. Kunzmann V. Thalheimer A. Hack M. Kleber G. et al.Concordance of KRAS/BRAF mutation status in metastatic colorectal cancer before and after anti-EGFR therapy.J Oncol. 2009 Mar 10; 2009: 831626Crossref PubMed Google Scholar, 81Etienne-Grimaldi M.-C. Formento J.-L. Francoual M. Francois E. Formento P. Renee N. et al.K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy.Clin Cancer Res. 2008 Aug; 14: 4830-4835Crossref PubMed Scopus (0) Google Scholar, 82Santini D. Loupakis F. Vincenzi B. Floriani I. Stasi I. Canestrari E. et al.High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice.Oncologist. 2008 Dec; 13: 1270-1275Crossref PubMed Scopus (205) Google Scholar, 83Artale S. Sartore-Bianchi A. Veronese S.M. Gambi V. Sarnataro C.S. Gambacorta M. et al.Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer.J Clin Oncol. 2008; 26 (Official Journal of the American Society of Clinical Oncology. United States): 4217-4219Crossref PubMed Scopus (208) Google Scholar, 84Gattenlohner S. Germer C. Muller-Hermelink H.-K. K-ras mutations and cetuximab in colorectal cancer.N Engl J Med. 2008; 360 (United States. [author reply 835–6]): 835Google Scholar, 85Weber J.-C. Meyer N. Pencreach E. Schneider A. Guerin E. Neuville A. et al.Allelotyping analyses of synchronous primary and metastasis CIN colon cancers identified different subtypes.Int J Cancer. 2007 Feb; 120: 524-532Crossref PubMed Scopus (27) Google Scholar, 86Oliveira C. Velho S. Moutinho C. Ferreira A. Preto A. Domingo E. et al.KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression.Oncogene. 2007 Jan; 26: 158-163Crossref PubMed Scopus (129) Google Scholar, 87Albanese I. Scibetta A.G. Migliavacca M. Russo A. Bazan V. Tomasino R.M. et al.Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations.Biochem Biophys Res Commun. 2004 Dec; 325: 784-791Crossref PubMed Scopus (79) Google Scholar, 88Zauber P. Sabbath-Solitare M. Marotta S.P. Bishop D.T. Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchronous metastases compared with the findings in accompanying adenomas.Mol Pathol. 2003 Jun 17; 56: 137-140Crossref PubMed Google Scholar, 89Tortola S. Steinert R. Hantschick M. Peinado M.A. Gastinger I. Stosiek P. et al.Discordance between K-ras mutations in bone marrow micrometastases and the primary tumor in colorectal cancer.J Clin Oncol. 2001 Jun; 19: 2837-2843Crossref PubMed Scopus (62) Google Scholar, 90Al-Mulla F. Going J.J. Sowden E.T. Winter A. Pickford I.R. Birnie G.D. Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality.J Pathol. 1998 Jun; 185: 130-138Crossref PubMed Scopus (114) Google Scholar, 91Suchy B. Zietz C. Rabes H.M. K-ras point mutations in human colorectal carcinomas: relation to aneuploidy and metastasis.Int J Cancer. 1992 Aug; 52: 30-33Crossref PubMed Google Scholar, 92Losi L. Benhattar J. Costa J. Stability of K-ras mutations throughout the natural history of human colorectal cancer.Eur J Cancer. 1992; 28A: 1115-1120Summary Full Text PDF PubMed Scopus (88) Google Scholar, 93Oudejans J.J. Slebos R.J. Zoetmulder F.A. Mooi W.J. Rodenhuis S. Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver.Int J Cancer. 1991 Dec; 49: 875-879Crossref PubMed Scopus (0) Google Scholar, 94Atreya C.E. Sangale Z. Xu N. Matli M.R. Tikishvili E. Welbourn W. et al.PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival.Cancer Med. 2013 Aug; 2: 496-506Crossref PubMed Scopus (0) Google Scholar, 95Yarom N. Marginean C. Moyana T. Gorn-Hondermann I. Birnboim H.C. Marginean H. et al.EGFR expression variance in paired colorectal cancer primary and metastatic tumors.Cancer Biol Ther. 2010 Sep; 10: 416-421Crossref PubMed Scopus (15) Google Scholar, 96Scartozzi M. Bearzi I. Berardi R. Mandolesi A. Fabris G. Cascinu S. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies.J Clin Oncol. 2004 Dec; 22: 4772-4778Crossref PubMed Scopus (245) Google Scholar, 97Jung J. Kang Y. Lee Y.J. Kim E. Ahn B. Lee E. et al.Comparison of the mismatch repair system between primary and metastatic colorectal cancers using immunohistochemistry.J Pathol Transl Med. 2017 Mar; 51: 129-136Crossref PubMed Scopus (6) Google Scholar, 98Haraldsdottir S. Roth R. Pearlman R. Hampel H. Arnold C.A. Frankel W.L. Mismatch repair deficiency concordance between primary colorectal cancer and corresponding metastasis.Familial Cancer. 2016; 15: 253-260Crossref PubMed Scopus (0) Google Scholar, 99Cohen S.A. Yu M. Baker K. Redman M. Wu C. Heinzerling T.J. et al.The CpG island methylator phenotype is concordant between primary colorectal carcinoma and matched distant metastases.Clin Epigenetics. 2017 May 2; 9: 46Crossref PubMed Scopus (1) Google Scholar, 100Kleist B. Meurer T. Poetsch M. Mitochondrial DNA alteration in primary and metastatic colorectal cancer: different frequency and association with selected clinicopathological and molecular markers.Tumour Biol. 2017 Mar; 39 (1010428317692246)Crossref PubMed Scopus (5) Google Scholar], and PIK3CA (n = 17) was 93% [42Higgins J.P.T. Thompson S.G. Deeks J.J. Altman D.G. Measuring inconsistency in meta-analyses.BMJ. 2003 Sep; 327: 557-560Crossref PubMed Google Scholar, 43Egger M. Smith G.D. Schneider M. Minder C. Bias in meta-analysis detected by a simple, graphical test.BMJ. 1997; 315: 629-634Crossref PubMed Google Scholar, 44Moorcraft S.Y. Jones T. Walker B.A. Ladas G. Kalaitzaki E. Yuan L. et al.Molecular profiling of colorectal pulmonary metastases and primary tumours: implications for targeted treatment.Oncotarget. 2017 Sep 12; 8: 64999-65008Crossref PubMed Scopus (2) Google Scholar, 45Fujiyoshi K. Yamamoto G. Takahashi A. Arai Y. Yamada M. Kakuta M. et al.High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases.Oncol Rep. 2017 Feb; 37: 785-792Crossref PubMed Scopus (52) Google Scholar, 46Petaccia de Macedo M. Melo F.M. Ribeiro H.S.C. Marques M.C. Kagohara L.T. Begnami M.D. et al.KRAS mutation status is highly homogeneous between areas of the primary tumor and the corresponding metastasis of colorectal adenocarcinomas: one less problem in patient care.Am J Cancer Res. 2017 Sep 1; 7: 1978-1989PubMed Google Scholar, 47Pang X.-L. Li Q.-X. Ma Z.-P. Shi Y. Ma Y.-Q. Li X.-X. et al.Association between clinicopathological features and survival in patients with primary and paired metastatic colorectal cancer and KRAS mutation.Onco Targets Ther. 2017 May 19; 10: 2645-2654Crossref PubMed Scopus (3) Google Scholar, 48Nemecek R. Berkovcova J. Radova L. Kazda T. Mlcochova J. Vychytilova-Faltejskova P. et al.Mutational analysis of primary and metastatic colorectal cancer samples underlying the resistance to cetuximab-based therapy.Onco Targets Ther. 2016 Jul 28; 9: 4695-4703Crossref PubMed Scopus (3) Google Scholar, 49Li Z.-Z. Bai L. Wang F. Zhang Z.-C. Wang F. Zeng Z.-L. et al.Comparison of KRAS mutation status between primary tumor and metastasis in Chinese colorectal cancer patients.Med Oncol. 2016 Jul; 33: 71Crossref PubMed Scopus (4) Google Scholar, 50He Q. Xu Q. Wu W. Chen L. Sun W. Ying J. Comparison of KRAS and PIK3CA gene status between primary tumors and paired metastases in colorectal cancer.Onco Targets Ther. 2016 Apr 20; 9: 2329-2335Crossref PubMed Scopus (0) Google Scholar, 51Kovaleva V. Geissler A.-L. Lutz L. Fritsch R. Makowiec F. Wiesemann S. et al.Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing.Mol Cancer. 2016 Oct 18; 15: 63Crossref PubMed Scopus (39) Google Scholar, 52Crumley S.M. Pepper K.L. Phan A.T. Olsen R.J. Schwartz M.R. Portier B.P. Next-generation sequencing of matched primary and metastatic rectal adenocarcinomas demonstrates minimal mutation gain and concordance to colonic adenocarcinomas.Arch Pathol Lab Med. 2016 Jun; 140: 529-535Crossref PubMed Scopus (7) Google Scholar, 53Vignot S. Lefebvre C. Frampton G.M. Meurice G. Yelensky R. Palmer G. et al.Comparative analysis of primary tumour and matched metastases in colorectal cancer patients: evaluation of concordance between genomic and transcriptional profiles.Eur J Cancer. 2015 May; 51: 791-799Summary Full Text Full Text PDF PubMed Google Scholar, 54Jesinghaus M. Wolf T. Pfarr N. Muckenhuber A. Ahadova A. Warth A. et al.Distinctive spatiotemporal stability of somatic mutations in metastasized microsatellite-stable colorectal cancer.Am J Surg Pathol. 2015 Aug; 39: 1140-1147Crossref PubMed Scopus (20) Google Scholar, 55Siyar Ekinci A. Demirci U. Cakmak Oksuzoglu B. Ozturk A. Esbah O. Ozatli T. et al.KRAS discordance between primary and metastatic tumor in patients with metastatic colorectal carcinoma.J BUON. 2015; 20: 128-135PubMed Google Scholar, 56Lau K.S. Lam K.O. Choy T.S. Shek W.H. Chung L.P. Leung T.W. Discordant RAS Status Between Primary and Metastatic Colorectal Cancer and Predicted Pattern of Metastases.26. 2015Summary Full Text Full Text PDF Google Scholar, 57Lee K.H. Kim J.S. Lee C.S. Kim J.Y. KRAS discordance between primary and recurrent tumors after radical resection of colorectal cancers.J Surg Oncol. 2015 Jun; 111: 1059-1064Crossref PubMed Scopus (13) Google Scholar, 58Lim B. Mun J. Kim J.-H. Kim C.W. Roh S.A. Cho D.-H. et al.Genome-wide mutation profiles of colorectal tumors and associated liver metastases at the exome and transcriptome levels.Oncotarget. 2015 Sep 8; 6: 22179-22190Crossref PubMed Scopus (17) Google Scholar, 59Kim R. Schell M.J. Teer J.K. Greenawalt D.M. Yang M. Yeatman T.J. co-evolution of somatic variation in primary and metastatic colorectal cancer may expand biopsy indications in the molecular era.PLoS One. 2015 May 14; 10 (Suzuki H, editor) (e0126670)Crossref Scopus (16) Google Scholar, 60Kleist B. Kempa M. Novy M. Oberkanins C. Xu L. Li G. et al.Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.Int J Clin Exp Pathol. 2014 Aug 15; 7: 5927-5939PubMed Google Scholar, 61Giannini R. Lupi C. Loupakis F. Servadio A. Cremolini C. Sensi E. et al.KRAS and BRAF genotyping of synchronous colorectal carcinomas.Oncol Lett. 2014 May 21; 7: 1532-1536Crossref PubMed Scopus (2) Google Scholar, 62PALIOGIANNIS P. COSSU A. TANDA F. PALMIERI G. PALOMBA G. KRAS mutational concordance between primary and metastatic colorectal adenocarcinoma.Oncol Lett. 2014 Oct 4; 8: 1422-1426Crossref PubMed Scopus (16) Google Scholar, 63Brannon A.R. Vakiani E. Sylvester B.E. Scott S.N. McDermott G. Shah R.H. et al.Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions.Genome Biol. 2014 Aug 28; 15: 454Crossref PubMed Scopus (255) Google Scholar, 64Lee S.Y. Haq F. Kim D. Jun C. Jo H.-J. Ahn S.-M. et al.Comparative genomic analysis of primary and synchronous metastatic colorectal cancers.PLoS One. 2014 Mar 5; 9 (Wikman H, editor) (e90459)Crossref Scopus (59) Google Scholar, 65Murata A. Baba Y. Watanabe M. Shigaki H. Miyake K. Ishimoto T. et al.Methylation levels of LINE-1 in primary lesion and matched metastatic lesions of colorectal cancer.Br J Cancer. 2013 Jul 23; 109: 408-415Crossref PubMed Scopus (30) Google Scholar, 66Miglio U. Mezzapelle R. Paganotti A. Allegrini S. Veggiani C. Antona J. et al.Mutation analysis of KRAS in primary colorectal cancer and matched metastases by means of highly sensitivity molecular assay.Pathol Res Pract. 2013 Apr; 209: 233-236Crossref PubMed Scopus (15) Google Scholar, 67Voutsina A. Tzardi M. Kalikaki A. Zafeiriou Z. Papadimitraki E. Papadakis M. et al.Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer.Mod Pathol. 2013 Aug 31; 26: 302Summary Full Text Full Text PDF PubMed Scopus (47) Google Scholar, 68Vakiani E. Janakiraman M. Shen R. Sinha R. Zeng Z. Shia J. et al.Comparative genomic analysis of primary versus metastatic colorectal carcinomas.J Clin Oncol. 2012 Aug; 30: 2956-2962Crossref PubMed Scopus (222) Google Scholar, 69Vermaat J.S. Nijman I.J. Koudijs M.J. Gerritse F.L. Scherer S.J. Mokry M. et al.Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment.Clin Cancer Res. 2012 Feb; 18: 688-699Crossref PubMed Scopus (127) Google Scholar, 70Knijn N. Mekenkamp L.J.M. Klomp M. Vink-Borger M.E. Tol J. Teerenstra S. et al.KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients.Br J Cancer. 2011 Mar; 104: 1020-1026Crossref PubMed Scopus (238) Google Scholar, 71Park J.H. Han S.-W. Oh D.-Y. Im S.-A. Jeong S.-Y. Park K.J. et al.Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.Cancer Chemother Pharmacol. 2011; 68: 1045-1055Crossref PubMed Scopus (56) Google Scholar, 72Watanabe T. Kobunai T. Yamamoto Y. Matsuda K. Ishihara S. Nozawa K. et al.Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer.Dis Colon Rectum. 2011 Sep; 54: 1170-1178Crossref PubMed Scopus (0) Google Scholar, 73Baldus S.E. Schaefer K.-L. Engers R. Hartleb D. Stoecklein N.H. Gabbert H.E. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.Clin Cancer Res. 2010 Feb; 16: 790-799Crossref PubMed Scopus (382) Google Scholar, 74Italiano A. Hostein I. Soubeyran I. Fabas T. Benchimol D. Evrard S. et al.KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.Ann Surg Oncol. 2010 May; 17: 1429-1434Crossref PubMed Scopus (101) Google Scholar, 75Mariani P. Lae M. Degeorges A. Cacheux W. Lappartient E. Margogne A. et al.Concordant analysis of KRAS status in primary colon carcinoma and matched metastasis.Anticancer Res. 2010 Oct; 30: 4229-4235PubMed Google Scholar, 76Perrone F. Lampis A. Orsenigo M. Di Bartolomeo M. Gevorgyan A. Losa M. et al.PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients.Ann Oncol Off J Eur Soc Med Oncol. 2009 Jan; 20: 84-90Summary Full Text Full Text PDF PubMed Scopus (0) Google Scholar, 77Cejas P. Lopez-Gomez M. Aguayo C. Madero R. de Castro Carpeno J. Belda-Iniesta C. et al.KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis.PLoS One. 2009 Dec; 4e8199Crossref Scopus (130) Google Scholar, 78Garm Spindler K.-L. Pallisgaard N. Rasmussen A.A. Lindebjerg J. Andersen R.F. Cruger D. et al.The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer.Ann Oncol Off J Eur Soc Med Oncol. 2009 May; 20: 879-884Summary Full Text Full Text PDF PubMed Scopus (0) Google Scholar, 79Molinari F. Martin V. Saletti P. De Dosso S. Spitale A. Camponovo A. et al.Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant.Br J Cancer. 2009 Apr 7; 100: 1087-1094Crossref PubMed Scopus (0) Google Scholar, 80Gattenlöhner S. Etschmann B. Kunzmann V. Thalheimer A. Hack M. Kleber G. et al.Concordance of KRAS/BRAF mutation status in metastatic colorectal cancer before and after anti-EGFR therapy.J Oncol. 2009 Mar 10; 2009: 831626Crossref PubMed Google Scholar, 81Etienne-Grimaldi M.-C. Formento J.-L. Francoual M. Francois E. Formento P. Renee N. et al.K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy.Clin Cancer Res. 2008 Aug; 14: 4830-4835Crossref PubMed Scopus (0) Google Scholar, 82Santini D. Loupakis F. Vincenzi B. Floriani I. Stasi I. Canestrari E. et al.High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice.Oncologist. 2008 Dec; 13: 1270-1275Crossref PubMed Scopus (205) Google Scholar, 83Artale S. Sartore-Bianchi A. Veronese S.M. Gambi V. Sarnataro C.S. Gambacorta M. et al.Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer.J Clin Oncol. 2008; 26 (Official Journal of the American Society of Clinical Oncology. United States): 4217-4219Crossref PubMed Scopus (208) Google Scholar, 84Gattenlohner S. Germer C. Muller-Hermelink H.-K. K-ras mutations and cetuximab in colorectal cancer.N Engl J Med. 2008; 360 (United States. [author reply 835–6]): 835Google Scholar, 85Weber J.-C. Meyer N. Pencreach E. Schneider A. Guerin E. Neuville A. et al.Allelotyping analyses of synchronous primary and metastasis CIN colon cancers identified different subtypes.Int J Cancer. 2007 Feb; 120: 524-532Crossref PubMed Scopus (27) Google Scholar, 86Oliveira C. Velho S. Moutinho C. Ferreira A. Preto A. Domingo E. et al.KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression.Oncogene. 2007 Jan; 26: 158-163Crossref PubMed Scopus (129) Google Scholar, 87Albanese I. Scibetta A.G. Migliavacca M. Russo A. Bazan V. Tomasino R.M. et al.Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations.Biochem Biophys Res Commun. 2004 Dec; 325: 784-791Crossref PubMed Scopus (79) Google Scholar, 88Zauber P. Sabbath-Solitare M. Marotta S.P. Bishop D.T. Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchronous metastases compared with the findings in accompanying adenomas.Mol Pathol. 2003 Jun 17; 56: 137-140Crossref PubMed Google Scholar, 89Tortola S. Steinert R. Hantschick M. Peinado M.A. Gastinger I. Stosiek P. et al.Discordance between K-ras mutations in bone marrow micrometastases and the primary tumor in colorectal cancer.J Clin Oncol. 2001 Jun; 19: 2837-2843Crossref PubMed Scopus (62) Google Scholar, 90Al-Mulla F. Going J.J. Sowden E.T. Winter A. Pickford I.R. Birnie G.D. Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality.J Pathol. 1998 Jun; 185: 130-138Crossref PubMed Scopus (114) Google Scholar, 91Suchy B. Zietz C. Rabes H.M. K-ras point mutations in human colorectal carcinomas: relation to aneuploidy and metastasis.Int J Cancer. 1992 Aug; 52: 30-33Crossref PubMed Google Scholar, 92Losi L. Benhattar J. Costa J. Stability of K-ras mutations throughout the natural history of human colorectal cancer.Eur J Cancer. 1992; 28A: 1115-1120Summary Full Text PDF PubMed Scopus (88) Google Scholar, 93Oudejans J.J. Slebos R.J. Zoetmulder F.A. Mooi W.J. Rodenhuis S. Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver.Int J Cancer. 1991 Dec; 49: 875-879Crossref PubMed Scopus (0) Google Scholar, 94Atreya C.E. Sangale Z. Xu N. Matli M.R. Tikishvili E. Welbourn W. et al.PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival.Cancer Med. 2013 Aug; 2: 496-506Crossref PubMed Scopus (0) Google Scholar, 95Yarom N. Marginean C. Moyana T. Gorn-Hondermann I. Birnboim H.C. Marginean H. et al.EGFR expression variance in paired colorectal cancer primary and metastatic tumors.Cancer Biol Ther. 2010 Sep; 10: 416-421Crossref PubMed Scopus (15) Google Scholar, 96Scartozzi M. Bearzi I. Berardi R. Mandolesi A. Fabris G. Cascinu S. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies.J Clin Oncol. 2004 Dec; 22: 4772-4778Crossref PubMed Scopus (245) Google Scholar, 97Jung J. Kang Y. Lee Y.J. Kim E. Ahn B. Lee E. et al.Comparison of the mismatch repair system between primary and metastatic colorectal cancers using immunohistochemistry.J Pathol Transl Med. 2017 Mar; 51: 129-136Crossref PubMed Scopus (6) Google Scholar, 98Haraldsdottir S. Roth R. Pearlman R. Hampel H. Arnold C.A. Frankel W.L. Mismatch repair deficiency concordance between primary colorectal cancer and corresponding metastasis.Familial Cancer. 2016; 15: 253-260Crossref PubMed Scopus (0) Google Scholar, 99Cohen S.A. Yu M. Baker K. Redman M. Wu C. Heinzerling T.J. et al.The CpG island methylator phenotype is concordant between primary colorectal carcinoma and matched distant metastases.Clin Epigenetics. 2017 May 2; 9: 46Crossref PubMed Scopus (1) Google Scholar, 100Kleist B. Meurer T. Poetsch M. Mitochondrial DNA alteration in primary and metastatic colorectal cancer: different frequency and association with selected clinicopathological and molecular markers.Tumour Biol. 2017 Mar; 39 (1010428317692246)Crossref PubMed Scopus (5) Google Scholar]. Meta-analytic pooled discordance was 8% for KRAS (95% CI = 5–10%), 8% for BRAF (95% CI = 5–10%), 7% for PIK3CA (95% CI = 2–13%), and 28% overall (95% CI = 14–44%). The liver was the most commonly biopsied metastatic site (n = 2276), followed by lung (n = 438), lymph nodes (n = 1123), and peritoneum (n = 132). Median absolute concordance in multiple biomarkers was 81% (5–95%).InterpretationMetastatic CRC demonstrates high concordance across multiple biomarkers, suggesting that molecular testing of either the primary or liver and lung metastasis is adequate. More research on colorectal peritoneal metastases is required.
Referência(s)